» Articles » PMID: 27292026

A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2016 Jun 14
PMID 27292026
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β-mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival.

Conclusions: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.

Citing Articles

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.


Signaling pathways in liver cancer: pathogenesis and targeted therapy.

Xue Y, Ruan Y, Wang Y, Xiao P, Xu J Mol Biomed. 2024; 5(1):20.

PMID: 38816668 PMC: 11139849. DOI: 10.1186/s43556-024-00184-0.


The Effects of Caloric Restriction on Inflammatory Targets in the Prostates of Aged Rats.

Rago V, Conforti F, La Russa D, Antonucci G, Urlandini L, Lofaro D Int J Mol Sci. 2024; 25(10).

PMID: 38791274 PMC: 11120753. DOI: 10.3390/ijms25105236.


Oct4 promoted proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in colon cancer cells by activating the SCF/c-Kit signaling pathway.

Bu X, Liu Y, Wang L, Yan Z, Xin G, Su W Cell Cycle. 2022; 22(3):291-302.

PMID: 36258646 PMC: 9851249. DOI: 10.1080/15384101.2022.2112486.


Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Xiong F, Wang Q, Wu G, Liu W, Wang B, Chen Y Biomark Res. 2022; 10(1):69.

PMID: 36104718 PMC: 9472737. DOI: 10.1186/s40364-022-00415-y.


References
1.
Dennler S, Itoh S, Vivien D, Ten Dijke P, Huet S, Gauthier J . Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998; 17(11):3091-100. PMC: 1170648. DOI: 10.1093/emboj/17.11.3091. View

2.
Wierenga A, Schuringa J, Eggen B, Kruijer W, Vellenga E . Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and -independent processes. Leukemia. 2002; 16(4):675-82. DOI: 10.1038/sj.leu.2402425. View

3.
Valdes F, Alvarez A, Locascio A, Vega S, Herrera B, Fernandez M . The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res. 2002; 1(1):68-78. View

4.
Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

5.
Lee D, Chung Y, Kim J, Lee Y, Lee D, Jang M . Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. Oncology. 2012; 82(1):11-8. DOI: 10.1159/000335605. View